FDA issues warning over Exactech shoulder implants at risk of oxidation
The FDA this week published a safety notice alerting patients and healthcare providers to possible risks linked to certain shoulder joint replacement implants.
The FDA this week published a safety notice alerting patients and healthcare providers to possible risks linked to certain shoulder joint replacement implants.
With Medtronic and Johnson & Johnson securing international approvals in the nascent domain of pulsed field ablation, Abbott is looking to join the party with its own approach for treating atrial fibrillation and other arrhythmias.
Following reports earlier this week that Apple had redesigned some versions of its eponymous smartwatch to remove them from the purview of a then-paused import ban, the tech giant has indeed begun selling altered versions of those Apple Watches in the U.S. as the ban takes effect once again.
Golden Biotechnology has shared updated data on its mushroom-derived drug candidate in metastatic pancreatic cancer, linking first-line use of the molecule to median overall survival (OS) of 14.1 months.
An open science competition held by a Canadian nonprofit has announced the discovery of molecules that could someday lead to new treatments for Parkinson’s disease.
Just as users around the world are surely strapping on new Fitbits with an aim of tackling health-focused New Year’s resolutions, so too is Fitbit itself kicking off 2024 with its sights set on a new goal.
Psychedelics-focused biotech Compass Pathways has signed a research collaboration with New Jersey’s Hackensack Meridian Health regarding the delivery model design of its investigational COMP360 psilocybin treatment.
The FDA has cleared its first artificial intelligence-powered device that checks out suspicious moles, bumps or lesions for the signs of skin cancer, with a handheld probe developed by DermaSensor.
Regenxbio and AbbVie have taken a small step toward in-office administration of their eye disease gene therapy candidate. Interim phase 2 data suggest the prospect can be given safely at the doctor’s office, opening up a convenient delivery option for the wet age-related macular degeneration (AMD) treatment.
For the third time since 2022, when it purchased infusion pump maker Ivenix for $240 million, Fresenius Kabi has earned a Class I rating from the FDA for a recall of the Ivenix medication delivery technology.